Redcare Pharmacy's Growth Premium Comes Under Scrutiny as Investors Look Past Record Margins
Published on 08/02/2026 at 18:31 | Redaktion boerse-global.de
The arithmetic of expectations can be unforgiving, even when the underlying numbers are strong. That was the lesson delivered to Redcare Pharmacy shareholders on Friday, when the Dutch online pharmacy delivered what many would consider a robust quarterly performance — record margins, an upgraded outlook, and accelerating prescription volumes — only to watch the stock shed 5.49 percent to close at EUR 61.95.
The selloff extends a broader pullback that has gathered pace in recent weeks. The shares are now down 6.49 percent over the past five sessions and nearly 11 percent on a monthly basis, leaving the stock more than 40 percent below its 52-week high of EUR 103.60 reached in August 2025.
A Growth Story That's Maturing
The market's reaction appears rooted less in the quarter itself than in what it signals about the company's trajectory. Redcare Pharmacy posted second-quarter revenue of EUR 854 million, with the group's half-year sales reaching EUR 1.7 billion — a 19 percent increase year over year. The adjusted EBITDA margin climbed to 3.5 percent, the highest level in a decade for the online pharmacy operator.
Yet the headline figures mask a subtle but significant shift. Where Redcare Pharmacy once compounded at roughly 25 percent annually, consensus projections now point to growth of around 12 percent per year going forward. That still dwarfs the 3.9 percent annual growth rate expected for the broader pharmacy market, but it represents a meaningful deceleration from the pace investors had grown accustomed to.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
The German prescription business, a key growth engine, expanded 58 percent in the quarter. Impressive on its face, but some market participants had anticipated an even stronger boost from the ongoing rollout of digital health infrastructure. The gap between what was delivered and what was hoped for proved decisive.
Analysts See Value Where the Market Sees Risk
The disconnect between the analyst community and the trading floor is striking. Rather than trimming their views, several major banks raised their price targets following the results.
UBS analyst Olivier Calvet lifted his target from EUR 60 to EUR 74, though he kept a "Neutral" rating. Calvet noted that the operating result positively surprised, while flagging the lack of acceleration in the German prescription business relative to the first quarter as a point to monitor. Deutsche Bank's Jan Koch was more effusive, raising his target from EUR 102 to EUR 103 with a "Buy" rating intact, describing the quarter as "outstanding" and positioning the company well for the remainder of 2026 and into 2027. Warburg Research remains among the most bullish houses on the street with a EUR 116 target.
The average analyst price target now stands at EUR 86.00, though the range is unusually wide — from EUR 55.00 to EUR 115.00 — reflecting genuine uncertainty about the company's trajectory. For the full year, analysts expect revenue of EUR 3.41 billion, a 6.0 percent increase, with the projected loss per share narrowing by roughly 70 percent to EUR 0.60.
Management, for its part, confirmed its upgraded guidance for 2026, maintaining expectations for revenue growth between 15 and 17 percent with an adjusted EBITDA margin of 2.5 to 3.0 percent. The third quarter is traditionally softer in the pharmacy sector, but the reaffirmed targets provide a fundamental anchor while the market digests the recent volatility.
Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.
Technical Picture Offers Little Clarity
On the charts, the stock sits in something of a neutral zone. The 14-day relative strength index reads 43.2, indicating neither overbought nor oversold conditions after the recent decline released some of the downward pressure. The shares remain 8.26 percent above their 200-day moving average of EUR 57.23, a level chart technicians view as an important support line for the longer-term uptrend that established itself over the summer.
The broader question hanging over the stock is whether Redcare Pharmacy can stabilize its growth trajectory at a level that justifies its premium valuation relative to the wider market. The company continues to outpace its industry by a wide margin, but the days of compounding at 25 percent appear to be behind it. For investors, the calculus has shifted: the stock now demands patience as much as conviction, with the wide dispersion in analyst targets underscoring just how divided the outlook has become.
Ad
Redcare Pharmacy Stock: New Analysis - 2 August
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
